Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laboratorio Farmaceutico Erfo SpAMIL:ERFO +1.33%70 Earnings Yield (Joel Greenblatt) % is 8.33% as of Dec. 2025, which is 10% below its 10-year median of 9.28. GuruFocus rates MIL:ERFO with a GF Score™ of 70/100 and a GF Value™ of €2.15 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 2,027 Consumer Packaged Goods companies, Laboratorio Farmaceutico Erfo SpA ranks better than 73.8% on this metric.
The historical rank and industry rank for Laboratorio Farmaceutico Erfo SpA's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
MIL:ERFO'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 3.84 Med: 9.28 Max: 14.81
Current: 10.54
During the past 7 years, the highest Earnings Yield (Joel Greenblatt) of Laboratorio Farmaceutico Erfo SpA was 14.81%. The lowest was 3.84%. And the median was 9.28%.
MIL:ERFO's Earnings Yield (Joel Greenblatt) % is ranked better than 73.8% of 2027
companies
in the Consumer Packaged Goods industry
Industry Median: 5.95
vs MIL:ERFO: 10.54
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Laboratorio Farmaceutico Erfo SpA's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 1.02%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Laboratorio Farmaceutico Erfo SpA's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorio Farmaceutico Erfo SpA Earnings Yield (Joel Greenblatt) % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Laboratorio Farmaceutico Erfo SpA's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Laboratorio Farmaceutico Erfo SpA's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 8.33% mean?
Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) has a Earnings Yield (Joel Greenblatt) % of 8.33% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Laboratorio Farmaceutico Erfo SpA and its competitors. This is 10% below median its historical median of 9.28. Over the past decade, Laboratorio Farmaceutico Erfo SpA's Earnings Yield (Joel Greenblatt) % has ranged from 3.84 to 14.81. According to the industry distribution chart, Laboratorio Farmaceutico Erfo SpA ranks #531 out of 2027 companies in the Consumer Packaged Goods industry, placing it in the top 26.2%.
Is Laboratorio Farmaceutico Erfo SpA's Earnings Yield (Joel Greenblatt) % too high?
Laboratorio Farmaceutico Erfo SpA's current Earnings Yield (Joel Greenblatt) % of 8.33% is 10% below median its 10-year median of 9.28. Over the past 10 years, this metric has ranged from a low of 3.84 to a high of 14.81. The Consumer Packaged Goods industry median Earnings Yield (Joel Greenblatt) % is 5.95. Laboratorio Farmaceutico Erfo SpA's value of 8.33% is 40% above this industry median. Based on the distribution chart, Laboratorio Farmaceutico Erfo SpA ranks #531 out of 2027 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Laboratorio Farmaceutico Erfo SpA has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorio Farmaceutico Erfo SpA's Earnings Yield (Joel Greenblatt) % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Laboratorio Farmaceutico Erfo SpA ranks #531 out of 2027 companies for Earnings Yield (Joel Greenblatt) %. This puts Laboratorio Farmaceutico Erfo SpA in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 5.95. Laboratorio Farmaceutico Erfo SpA's value of 8.33% is 40% above this benchmark. Historically, Laboratorio Farmaceutico Erfo SpA's own Earnings Yield (Joel Greenblatt) % has ranged from 3.84 to 14.81 over the past decade. While the company's 10-year median is 9.28 vs. the industry median of 5.95, Laboratorio Farmaceutico Erfo SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Consumer Packaged Goods company?
The median Earnings Yield (Joel Greenblatt) % among Consumer Packaged Goods companies is 5.95, based on 2,027 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorio Farmaceutico Erfo SpA's current Earnings Yield (Joel Greenblatt) % of 8.33% is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Laboratorio Farmaceutico Erfo SpA and its competitors. For the Consumer Packaged Goods industry, the median Earnings Yield (Joel Greenblatt) % is 5.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorio Farmaceutico Erfo SpA's current Earnings Yield (Joel Greenblatt) % is 8.33%, which is 10% below median its own 10-year median of 9.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorio Farmaceutico Erfo SpA stock overvalued right now?
Based on GuruFocus' analysis, Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.15, compared to a current price of €1.14 — trading 47% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 8.33%, which is 10% below median its 10-year median of 9.28 and 40% above the Consumer Packaged Goods industry median of 5.95. Laboratorio Farmaceutico Erfo SpA's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Laboratorio Farmaceutico Erfo SpA (MIL:ERFO), the current Earnings Yield (Joel Greenblatt) % is 8.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorio Farmaceutico Erfo SpA stock appears to be undervalued.
The current stock price of €1.14 is trading 47% below its estimated GF Value™ of €2.15.
GuruFocus considers Laboratorio Farmaceutico Erfo SpA to be Significantly Undervalued.
Key valuation signals for MIL:ERFO:
Earnings Yield (Joel Greenblatt) %: 8.33% (10% below median its 10-year median of 9.28)
GF Value™: €2.15 vs. price of €1.14 (47% below fair value)
Industry Position: 40% above the Consumer Packaged Goods median (#531 of 2027)
No single metric tells the full story. See the MIL:ERFO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorio Farmaceutico Erfo SpA operates in the nutraceutical sector. The company specializes in formulating and producing food supplements and natural medicines in different forms such as liquids, powders, granules, tablets, and soft gels. Geographically, the company generates a majority of its revenue from Italy followed by Spain, France, Belgium, and other countries.
70GF Score
Get the complete analysis for MIL:ERFO
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:ERFO has been successfully added to your 
